YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria

Diabetes Care

Volumn 32, Issue 2, 2009, Pages 323-328

  Rathcke, Camilla Noelle ^a   Persson, Frederik ^b   Tarnow, Lise ^b   Rossing, Peter ^b   Vestergaard, Henrik ^a,c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b STENO DIABETES CENTER   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; BIOLOGICAL MARKER; CHI3L1 PROTEIN, HUMAN; GLYCOPROTEIN;

ADULT; ALBUMINURIA; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; URINARY EXCRETION; AGED; BLOOD; BLOOD PRESSURE; DIABETIC ANGIOPATHY; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MIDDLE AGED; REFERENCE VALUE;

ADULT; AGED; ALBUMINURIA; BIOLOGICAL MARKERS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; FEMALE; GLYCOPROTEINS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; REFERENCE VALUES;

EID: 61849086267     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-1144     Document Type: Article

References (25)

1. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS: Urinary albumin excretion: an independent predictor of ischemic heart disease. Arte- rioscler Thromb Vasc Biol 19:1992-1997, 1999
2. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286: 421-426, 2001
3. Rossing P, Hougaard P, Parving H-H: Progression of microalbuminuria in type 1 diabetes: ten-year prospective observational study. Kidney Int 68:1446-1450, 2005
4. Stamler J, Vaccaro O, Neaton JD, Went- worth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434-444, 1993
5. Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, Gatling W, Bin- gley PJ, Patterson CC: Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Dia- betologia 46:760-765, 2003
6. Hovind P, Tarnow L, Rossing K, Rossing P, Eising S, Larsen N, Binder C, Parving H-H: Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 26:1258-1264, 2003
7. Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J: Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 330: 15-18, 1994
8. Laing SP, Swerdlow AJ, Slater SD, Botha JL, Burden AC, Waugh NR, Smith AW, Hill RD, Bingley PJ, Patterson CC, Qiao Z, Keen H: The British Diabetic Association Cohort Study, II: cause-specific mortality in patients with insulin- treated diabetes mellitus. Diabet Med 16:466-471, 1999
9. Deckert T, Feldt-Rasmussen B, Borch- Johnsen K, Jensen T, Kofoed-Enevoldsen A: Albuminuria reflects widespread vascular damage: the Steno hypothesis. Dia- betologia 32:219-226, 1989
10. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 105: 1135-1143, 2002
11. Rathcke CN, Vestergaard H: YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endo- thelial dysfunction and atherosclerosis. Inflamm Res 55:221-227, 2006
12. Millis AJ, Hoyle M, Kent L: In vitro expression of a 38,000 dalton heparin-bind- ing glycoprotein by morphologically differentiated smooth muscle cells. J Cell Physiol 127:366-372, 1986
13. Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Millis AJ: Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 250:168-173, 1999
14. Shackelton LM, Mann DM, Millis AJ: Identification of a 38-kDa heparin-bind- ing glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem 270: 13076-13083, 1995
15. Rathcke CN, Johansen JS, Vestergaard H: YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflamm Res 55:53-59, 2006
16. Rathcke CN, Raymond I, Kistorp C, Faber J, Vestergaard H: The inflammation marker YKL-40 is elevated in patients with type 2 diabetes and is associated with an increased mortality rate in normal individuals after adjustment for risk factors of cardiovascular events (Abstract). Diabetologia 50:s103, 2007
17. Jager A, van HV, Kostense PJ, Emeis JJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD: C-reactive protein and soluble vascular cell adhesion mole- cule-1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk. Arterioscler Thromb Vasc Biol 22:593-598, 2002
18. Schalkwijk CG, Stehouwer CD: Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond) 109:143-159, 2005
19. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD: Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetologia 48:370-378, 2005
20. Astrup AS, Tarnow L, Pietraszek L, Schalkwijk CG, Stehouwer CD, Parving H-H, Rossing P: Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glo- merular filtration rate. Diabetes Care 31: 1170-1176, 2008
21. Devaraj S, Cheung AT, Jialal I, Griffen SC, Nguyen D, Glaser N, Aoki T: Evidence of increased inflammation and microcircu- latory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes 56:2790-2796, 2007
22. Kucur M, Isman FK, Karadag B, Vural VA, Tavsanoglu S: Serum YKL-40 levels in patients with coronary artery disease. Coron Artery Dis 18:391-396, 2007
23. Nojgaard C, Host NB, Christensen IJ, Poulsen SH, Egstrup K, Price PA, Johan- sen JS: Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis 19:257-263, 2008
24. Johansen JS: Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 53:172-209, 2006
25. Roslind A, Knoop AS, Jensen MB, Johan- sen JS, Nielsen DL, Price PA, Balslev E: YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer. Breast Cancer Res Treat 112: 275-285, 2008